Lineage Cell Therapeutics, Inc. reported Q4 and full year 2025 financial results, including Q4 revenues of $6.6 million, net income of $0.9 million or $0.004 per share, and cash of $55.8 million as of December 31, 2025, expected to support operations into Q2 2028. Key highlights include achieving the first milestone under the Roche/Genentech collaboration for RG6501 (OpRegen) and positive 36-month Phase 1/2a study results.
Key takeaways
Achieved first milestone under $620 million worldwide collaboration with Roche and Genentech for RG6501 (OpRegen) based on manufacturing and clinical advancements
Positive 36-month Phase 1/2a results for RG6501 (OpRegen) in Cohort 4 (12 patients) showed sustained visual acuity gains and retinal support
Q4 2025 revenues $6.6 million vs $2.9 million in Q4 2024; full year 2025 revenues $14.6 million vs $9.5 million in 2024
Q4 2025 net income $0.9 million or $0.004 per share vs net loss $3.3 million or $0.02 per share in Q4 2024
Cash, cash equivalents, and marketable securities $55.8 million as of December 31, 2025, plus $5.4 million warrant proceeds in March 2026, supports operations into Q2 2028
Entered research collaboration with William Demant Invest A/S for ReSonance (ANP1) with up to $12 million development funding over three years
Treated first chronic SCI patient in OPC1 DOSED study with no significant safety events at 180 days